OSI Pharmaceuticals maintained at buy: Merrill

OSI Pharmaceuticals, Inc. was maintained at buy by Merrill Lynch analysts Eric Ende, Thomas J. McGahren and David Munno following the company's announcement it will acquire Eyetech Pharmaceuticals. Merrill said investors are underestimating the company's Tarceva sales potential. OSI stock closed down $8.85, or 21.71%, at $31.92 on Monday on volume of 27,646,741 shares compared to a three-month trailing average of 1,335,540 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.